GRAND RAPIDS, Mich. and ZURICH, Switzerland, Jan. 26, 2016 (SEND2PRESS NEWSWIRE) — eAgile Inc., a global leader in radio frequency identification (RFID) technologies, announces the successful high-volume production launch of the eSeal heat induction solution. eSeal is the first turnkey solution engineered to integrate the benefits of RFID into the billions of caps and closures […]
IRVING, Texas, Dec. 30, 2015 (SEND2PRESS NEWSWIRE) — A current BioTE(R) Medical Combat Trauma Treatment Study (in conjunction with the Veterans Advocacy Center (VAC)) is showing promising results in helping veterans suffering from Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).
NEW YORK, N.Y., Dec. 7, 2015 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus […]
COSTA MESA, Calif., Oct. 12, 2015 (SEND2PRESS NEWSWIRE) — Many insurance plans are dropping coverage of compounded medications, but some insurance plans still do cover for these custom formulations. Harbor Compounding Pharmacy provides resources and referrals to patients to find insurance coverage for their compounded medications during open enrollment 2016.
NEW YORK, N.Y. and Tokyo, Sept. 15, 2015 (SEND2PRESS NEWSWIRE) — Eularis announces today the release of E-VAI, the latest development in sophisticated artificial intelligence technology delivering next generation analytics and decision making to Pharma marketers globally. E-VAI changes the game for marketers struggling to understand and get value from their marketing.
NEW YORK, N.Y., April 7, 2015 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., announced it is accepting cases of congenital heart defects and cleft facial abnormalities in children whose mothers took the prescription drug Zofran during pregnancy to relieve symptoms of morning sickness.
NEW YORK, N.Y., Feb. 11, 2015 (SEND2PRESS NEWSWIRE) — Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs’ steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.
PORTLAND, Ore., April 9, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.
PORTLAND, Ore., Oct. 9, 2013 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc. today announced that it has signed a distribution agreement with Horus Pharma for rights to supply the Ilast(R) range of its medical-grade ocular hygiene and lid care products within the United States; it begins on an exclusive basis this month.
DURHAM, N.C., Sept. 4, 2013 (SEND2PRESS NEWSWIRE) — HeartIT, the global leader that pioneered the first FDA approved zero-footprint medical imaging workstation, announced today that it has received a $2.5M grant from the NIH in order to develop the ‘Cloud Based Corelab of the Future.’
NEW YORK CITY, N.Y., July 11, 2013 (SEND2PRESS NEWSWIRE) — Stem cell therapy research and treatment will now be available at the Blue Horizon International (BHI) laboratory at the Medissimo Hospital in Bratislava, Slovakia. BHI, along with its local partner, will host a press conference and ribbon-cutting ceremony where its research and treatment lab will […]
MADISON, N.J. and TIGARD, Ore., April 19, 2013 (SEND2PRESS NEWSWIRE) — Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.
ATLANTA, Ga. (SEND2PRESS NEWSWIRE) — CMI and Pfizer will co-present ‘Engaging Stakeholders with A Story – 3 Tips to Improve Research Reporting’ at the PMRG’s upcoming National Annual Conference March 10-12 in National Harbor, Md.
ATLANTA, Ga. (SEND2PRESS NEWSWIRE) — CMI, a leader in marketing research services and insight, announced today that Beth Thompson has joined as Vice President, Qualitative Research. Thompson brings a 20-year track record of successfully conducting highly complex domestic and global marketing research.
BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — In the early 1980’s George Coleman, head of Dermedics Laboratories in Bridgeport, Conn., teamed up with the former Keneric Industries to reformulate and market an over-the-counter pharmaceutical product designed to treat the symptoms of hangovers. The product, Dr. Seltzer’s Hangover Helper, went on to become the best-selling hangover remedy in […]
HIGHLAND PARK, N.J., Feb. 1, 2012 (SEND2PRESS NEWSWIRE) — 2012 marks an important milestone for Belvidere Pharmacy. It opened new doors in its new hometown of Highland Park. When owner and President Shara Rudner, R.Ph. took the reins of the business in 1996, it was a typical retail pharmacy stocked with everything from school to […]
MALVERN, Pa., Oct. 31, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.
MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no […]
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.
NORTH PLAINFIELD, N.J. (SEND2PRESS NEWSWIRE) — For the second time in its history, Belvidere Pharmacy of North Plainfield has secured the coveted Pharmacy Compounding Accreditation Board’s (PCAB) Seal of Accreditation. Registered in New York, New Jersey and Connecticut, Belvidere was the first and is still the only accredited PCAB pharmacy in the New York metro […]
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company’s lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form […]
MALVERN, Pa. (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 […]
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two […]
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled ‘Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma’ at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. […]
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the clinical results of the study entitled ‘A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the […]
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled ‘Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer’ (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector […]
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus […]
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety of Rexin-G, advanced U.S. Phase I/II studies were undertaken, […]
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world’s first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has once again accomplished what standard cancer […]
FORT LAUDERDALE, Fla. (SEND2PRESS NEWSWIRE) — Argentech, Inc. today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver, a patented antibacterial and antiviral technology that utilizes ionic silver in a unique complex for optimal delivery in the human body. The complex was granted broad patent protection in […]